- Keith Alcorn | 21 March 2013
Offering people the opportunity to self-test at home and
then start antiretroviral therapy after counselling at home, together with home
delivery of antiretroviral drugs, increased the number of people linked to care
after ...
- Liz Highleyman | 20 March 2013
A simple 24-week oral regimen consisting of
sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated
people with genotype 1 hepatitis C, many of whom had factors predictive of poor
response, researchers
reported ...
- Liz Highleyman | 20 March 2013
All-oral regimens consisting of the HCV protease
inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to
sustained response for more than 90% of previously untreated hepatitis C patients – including those ...
- Gus Cairns | 15 March 2013
Several presentations at the recent 20th
Conference on Retroviruses and Opportunistic Infections in Atlanta suggest that previous estimates of the proportion of
people with HIV in the USA who are on antiretroviral ...
- Carole Leach-Lemens | 14 March 2013
A ritonavir-boosted lopinavir (LPV/r)-based
regimen achieved a comparable rate of virologic suppression when compared to a non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen in HIV-infected Ugandan
children at 48 weeks, with comparable immunological responses ...
- Gus Cairns | 13 March 2013
Gene therapy approaches that involve the genetic modification of human haematopoietic stem cells have the potental to engineer HIV control by introducing cells resistant to HIV infection, the 20th ...
- Liz Highleyman | 12 March 2013
Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the
duration of treatment and increases the likelihood of a cure for HIV-positive
men with acute sexually transmitted hepatitis C virus ...
- Liz Highleyman | 12 March 2013
An all-oral combination of
simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for
most hard-to-treat prior null responders with genotype 1 hepatitis C studied in
the phase 2a COSMOS ...
- Carole Leach-Lemens | 12 March 2013
Eighteen months after implementation of 'Option B+' in Malawi – ART for life for all HIV-infected,
pregnant or breastfeeding women regardless of CD4 count or disease stage – the
number of HIV-infected ...
- Lesley Odendal | 12 March 2013
Six-monthly viral load testing of
patients taking antiretroviral therapy (ART) at primary health clinics in rural Kenya reduced the risk
of virologic failure at 18 months of follow-up by 46%, according to ...
- Liz Highleyman | 11 March 2013
Adding the hepatitis C virus
(HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and
ribavirin led to a higher early response rate and the potential for shorter
treatment for HIV/HCV co-infected ...
- Liz Highleyman | 11 March 2013
Adding the new hepatitis C
virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and
ribavirin cures about three-quarters of HIV/HCV co-infected people, most of
them with a shortened course of therapy, ...
- Roger Pebody | 10 March 2013
The concerns about a possible increase in risk of HIV acquisition with some hormonal contraceptive methods need to be understood in the context of the substantial uncertainties in the body ...
- Liz Highleyman | 10 March 2013
The next-generation integrase
inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for
treatment-experienced people with resistance to two or more antiretroviral drug
classes, researchers reported in a poster presented at the 20th Conference on Retroviruses and ...
- Keith Alcorn | 07 March 2013
A second-line antiretroviral regimen of lopinavir/ritonavir
(Kaletra/Aluvia) and raltegravir (Isentress) proved just as effective as a
regimen containing lopinavir/ritonavir and two or three nucleoside or nucleotide analogues in large
study conducted in Australia, ...
- Liz Highleyman | 07 March 2013
Omitting nucleoside reverse transcriptase inhibitors (NRTIs)
when switching from a non-suppressive regimen to a new combination with at
least two active agents can reduce pill burden and side-effects without
compromising effectiveness, researchers reported ...
- Liz Highleyman | 07 March 2013
Tenofovir alafenamide fumarate or TAF (formerly
GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells
harbouring HIV more easily than the older tenofovir disoproxil fumarate (TDF), allowing
for similar antiviral ...
- Gus Cairns | 07 March 2013
Progress towards greater coverage of voluntary male
circumcision (MC) in Africa remains slow, and is due as much to men’s fear of
the operation as it is to resource constraints, despite low ...
- Keith Alcorn | 07 March 2013
Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at
much higher doses than used in current clinical practice – suggesting that much
higher drug levels may lead to a ...
- Keith Alcorn | 07 March 2013
A new two-drug combination of rifapentine and moxifloxacin
can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month
continuation phase, Dr Amina Jindani of St George’s University Medical School,
London, told ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...